Cargando…
Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases
OBJECTIVE: To evaluate the efficacy of mixed oral prednisolone and intratympanic dexamethasone (ITID) injection in labyrinthitis, due to COVID 19. METHODS: Seventy-five post-COVID-19 labyrinthitis patients were included. Those patients were treated with systemic oral prednisolone for two weeks and I...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384350/ https://www.ncbi.nlm.nih.gov/pubmed/35989722 http://dx.doi.org/10.1016/j.amsu.2022.104429 |
_version_ | 1784769433394216960 |
---|---|
author | Ismaiel, Wael F. Abdelazim, Mohamed H. Wahba, Ashraf A. Alsobky, Mahmoud E. Ibrahim, Ahmed Abdalrhman Ghanem, Soliman A. Rabaan, Ali A. Ismail, Elshahat I. |
author_facet | Ismaiel, Wael F. Abdelazim, Mohamed H. Wahba, Ashraf A. Alsobky, Mahmoud E. Ibrahim, Ahmed Abdalrhman Ghanem, Soliman A. Rabaan, Ali A. Ismail, Elshahat I. |
author_sort | Ismaiel, Wael F. |
collection | PubMed |
description | OBJECTIVE: To evaluate the efficacy of mixed oral prednisolone and intratympanic dexamethasone (ITID) injection in labyrinthitis, due to COVID 19. METHODS: Seventy-five post-COVID-19 labyrinthitis patients were included. Those patients were treated with systemic oral prednisolone for two weeks and ITID. Patients who refuse ITID were ordered to continue oral prednisolone treatment. Assessment of outcome and audiometry for hearing evaluation was done 1, 2 and 4 weeks as well as 3 months post-treatment. RESULTS: Patients in oral steroid only group were 26 patients, while patients in oral steroid and ITID group were 49 patients. In oral steroid group; 11/26 patients showed complete recovery, 3/26 had partial recovery and 12/26 not recovered. In other group; 38/46 patients had complete recovery, 6 had partial recovery and 5/49 patients not recovered. CONCLUSION: Combined systemic corticosteroid with ITID showed a marked improvement of post-COVID vestibular disorder and hearing loss than only using oral corticosteroid therapy. |
format | Online Article Text |
id | pubmed-9384350 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-93843502022-08-17 Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases Ismaiel, Wael F. Abdelazim, Mohamed H. Wahba, Ashraf A. Alsobky, Mahmoud E. Ibrahim, Ahmed Abdalrhman Ghanem, Soliman A. Rabaan, Ali A. Ismail, Elshahat I. Ann Med Surg (Lond) Cohort Study OBJECTIVE: To evaluate the efficacy of mixed oral prednisolone and intratympanic dexamethasone (ITID) injection in labyrinthitis, due to COVID 19. METHODS: Seventy-five post-COVID-19 labyrinthitis patients were included. Those patients were treated with systemic oral prednisolone for two weeks and ITID. Patients who refuse ITID were ordered to continue oral prednisolone treatment. Assessment of outcome and audiometry for hearing evaluation was done 1, 2 and 4 weeks as well as 3 months post-treatment. RESULTS: Patients in oral steroid only group were 26 patients, while patients in oral steroid and ITID group were 49 patients. In oral steroid group; 11/26 patients showed complete recovery, 3/26 had partial recovery and 12/26 not recovered. In other group; 38/46 patients had complete recovery, 6 had partial recovery and 5/49 patients not recovered. CONCLUSION: Combined systemic corticosteroid with ITID showed a marked improvement of post-COVID vestibular disorder and hearing loss than only using oral corticosteroid therapy. Elsevier 2022-08-17 /pmc/articles/PMC9384350/ /pubmed/35989722 http://dx.doi.org/10.1016/j.amsu.2022.104429 Text en © 2022 The Authors https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Cohort Study Ismaiel, Wael F. Abdelazim, Mohamed H. Wahba, Ashraf A. Alsobky, Mahmoud E. Ibrahim, Ahmed Abdalrhman Ghanem, Soliman A. Rabaan, Ali A. Ismail, Elshahat I. Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases |
title | Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases |
title_full | Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases |
title_fullStr | Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases |
title_full_unstemmed | Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases |
title_short | Intratympanic injection of dexamethasone for management of labyrinthitis associated with COVID-19 disease resistant cases |
title_sort | intratympanic injection of dexamethasone for management of labyrinthitis associated with covid-19 disease resistant cases |
topic | Cohort Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9384350/ https://www.ncbi.nlm.nih.gov/pubmed/35989722 http://dx.doi.org/10.1016/j.amsu.2022.104429 |
work_keys_str_mv | AT ismaielwaelf intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases AT abdelazimmohamedh intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases AT wahbaashrafa intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases AT alsobkymahmoude intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases AT ibrahimahmedabdalrhman intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases AT ghanemsolimana intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases AT rabaanalia intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases AT ismailelshahati intratympanicinjectionofdexamethasoneformanagementoflabyrinthitisassociatedwithcovid19diseaseresistantcases |